CL2019003259A1 - Compuesto de insulina acilada. - Google Patents
Compuesto de insulina acilada.Info
- Publication number
- CL2019003259A1 CL2019003259A1 CL2019003259A CL2019003259A CL2019003259A1 CL 2019003259 A1 CL2019003259 A1 CL 2019003259A1 CL 2019003259 A CL2019003259 A CL 2019003259A CL 2019003259 A CL2019003259 A CL 2019003259A CL 2019003259 A1 CL2019003259 A1 CL 2019003259A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- insulin compound
- acylated insulin
- refer
- acillated
- Prior art date
Links
- -1 Acylated insulin compound Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
LOS COMPUESTOS DESCRITOS EN LA PRESENTE SE REFIEREN AL TRATAMIENTO DE LA DIABETES Y/O HIPERGLUCEMIA. MÁS PARTICULARMENTE+, LOS COMPUESTOS DESCRITOS SE REFIEREN A COMPUESTOS DE INSULINA ACILADA QUE REDUCEN LA GLUCOSA EN SANGRE, COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN TALES COMPUESTOS, USOS TERAPÉUTICOS DE TALES COMPUESTOS Y UN COMPUESTO INTERMEDIARIO USADO PARA ELABORAR LOS COMPUESTOS DE INSULINA ACILADA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511690P | 2017-05-26 | 2017-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003259A1 true CL2019003259A1 (es) | 2020-04-17 |
Family
ID=62528889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003259A CL2019003259A1 (es) | 2017-05-26 | 2019-11-14 | Compuesto de insulina acilada. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10400021B2 (es) |
| EP (1) | EP3630165A1 (es) |
| JP (1) | JP6665349B2 (es) |
| KR (1) | KR102271057B1 (es) |
| CN (1) | CN110691608B (es) |
| AR (1) | AR112353A1 (es) |
| AU (1) | AU2018273777B2 (es) |
| BR (1) | BR112019021668A2 (es) |
| CA (1) | CA3065078C (es) |
| CL (1) | CL2019003259A1 (es) |
| CO (1) | CO2019012964A2 (es) |
| CR (1) | CR20190523A (es) |
| DO (1) | DOP2019000296A (es) |
| EA (1) | EA038073B1 (es) |
| EC (1) | ECSP19083930A (es) |
| IL (1) | IL270813B1 (es) |
| JO (1) | JOP20190273A1 (es) |
| MA (1) | MA49310A (es) |
| MX (1) | MX2019014086A (es) |
| PE (1) | PE20191836A1 (es) |
| PH (1) | PH12019502655A1 (es) |
| SA (1) | SA519410448B1 (es) |
| TW (1) | TWI672315B (es) |
| WO (1) | WO2018217573A1 (es) |
| ZA (1) | ZA201906955B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022511567A (ja) | 2018-12-11 | 2022-01-31 | サノフイ | インスリンコンジュゲート |
| TW202120536A (zh) | 2019-07-31 | 2021-06-01 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| US20240025957A1 (en) * | 2019-12-30 | 2024-01-25 | Gan & Lee Pharmaceuticals Co., Ltd. | Insulin Derivative |
| JP7456007B2 (ja) * | 2020-05-15 | 2024-03-26 | イーライ リリー アンド カンパニー | 長時間作用アシル化インスリン化合物 |
| US20230374045A1 (en) | 2022-05-18 | 2023-11-23 | Protomer Technologies Inc. | Aromatic boron-containing compounds and related insulin analogs |
| WO2024051787A1 (zh) * | 2022-09-09 | 2024-03-14 | 北京惠之衡生物科技有限公司 | 一种长效酰化胰岛素衍生物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0004169A3 (en) * | 1997-10-24 | 2001-06-28 | Lilly Co Eli | Insoluble insulin compositions and process for production thereof |
| US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| EP1660531A2 (en) * | 2003-08-05 | 2006-05-31 | Novo Nordisk A/S | Novel insulin derivatives |
| US20080171695A1 (en) | 2005-02-02 | 2008-07-17 | Novo Nordisk A/S | Insulin Derivatives |
| KR20100053561A (ko) * | 2007-08-15 | 2010-05-20 | 노보 노르디스크 에이/에스 | 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체 |
| WO2009022006A1 (en) | 2007-08-15 | 2009-02-19 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
| HUE032284T2 (en) * | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| EP2376520B1 (en) * | 2008-12-19 | 2014-02-12 | Indiana University Research&Technology Corporation | Insulin analogs |
| EP2976096B1 (en) | 2013-03-20 | 2019-02-27 | Novo Nordisk A/S | Insulin dosing regimen |
| JP2016519127A (ja) * | 2013-04-30 | 2016-06-30 | ノヴォ ノルディスク アー／エス | 新規投与レジメン |
| AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
-
2017
- 2017-06-16 JO JOP/2019/0273A patent/JOP20190273A1/ar unknown
-
2018
- 2018-05-11 AR ARP180101254 patent/AR112353A1/es unknown
- 2018-05-11 TW TW107116025A patent/TWI672315B/zh active
- 2018-05-18 CR CR20190523A patent/CR20190523A/es unknown
- 2018-05-18 JP JP2019520536A patent/JP6665349B2/ja active Active
- 2018-05-18 CN CN201880034670.1A patent/CN110691608B/zh active Active
- 2018-05-18 WO PCT/US2018/033418 patent/WO2018217573A1/en active Application Filing
- 2018-05-18 KR KR1020197034368A patent/KR102271057B1/ko active Search and Examination
- 2018-05-18 PE PE2019002403A patent/PE20191836A1/es unknown
- 2018-05-18 EA EA201992272A patent/EA038073B1/ru unknown
- 2018-05-18 US US15/983,167 patent/US10400021B2/en active Active
- 2018-05-18 BR BR112019021668-5A patent/BR112019021668A2/pt unknown
- 2018-05-18 CA CA3065078A patent/CA3065078C/en active Active
- 2018-05-18 MA MA049310A patent/MA49310A/fr unknown
- 2018-05-18 AU AU2018273777A patent/AU2018273777B2/en active Active
- 2018-05-18 MX MX2019014086A patent/MX2019014086A/es active IP Right Grant
- 2018-05-18 EP EP18729289.1A patent/EP3630165A1/en active Pending
- 2018-05-18 IL IL270813A patent/IL270813B1/en unknown
-
2019
- 2019-08-01 US US16/529,095 patent/US10597436B2/en active Active
- 2019-10-22 ZA ZA2019/06955A patent/ZA201906955B/en unknown
- 2019-10-31 SA SA519410448A patent/SA519410448B1/ar unknown
- 2019-11-14 CL CL2019003259A patent/CL2019003259A1/es unknown
- 2019-11-19 CO CONC2019/0012964A patent/CO2019012964A2/es unknown
- 2019-11-22 DO DO2019000296A patent/DOP2019000296A/es unknown
- 2019-11-25 PH PH12019502655A patent/PH12019502655A1/en unknown
- 2019-11-25 EC ECSENADI201983930A patent/ECSP19083930A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003259A1 (es) | Compuesto de insulina acilada. | |
| BR112016016290A2 (pt) | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina | |
| ECSP13012661A (es) | Composición farmacéutica, métodos de tratamiento y usos de la misma. | |
| AR099569A1 (es) | Derivados de insulina y los usos médicos de estos | |
| CL2019001586A1 (es) | Insulina que contiene composiciones farmacéuticas. | |
| AR106364A1 (es) | Derivados de insulina y sus usos médicos | |
| BR112015014372A8 (pt) | inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas". | |
| CO6640324A2 (es) | Uso de metformina en combinación con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa | |
| CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
| PH12016500296A1 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| BR112013001301A2 (pt) | processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana | |
| JOP20210201A1 (ar) | مركب لخفض جلوكوز الدم | |
| CR20140473A (es) | Compuestos de pirazol como inhibidores de sglt1 | |
| ECSP22087958A (es) | Compuestos de insulina acilada de acción temporal prolongada | |
| CO2022007273A2 (es) | Análogos de insulina novedosos y usos de estos | |
| CL2020000310A1 (es) | Análogos de insulina acilados novedosos y usos de estos. | |
| CR20160508A (es) | Un profármaco de 1,1´-(1,6-dioxo-1,6-hexanodiilo)bis-d-prolina | |
| BR102018010523A2 (pt) | peptídeo, composição farmacêutica compreendendo o mesmo e uso | |
| TH172399A (th) | การบำบัดโรคเบาหวานด้วยสูตรผสมอินซูลินที่ออกฤทธิ์นาน | |
| PL413779A1 (pl) | Zastosowanie medyczne 4-cykloheksylo-1-(4-nitrofenylo)-karbonylotiosemikarbazydu oraz kompozycja farmaceutyczna | |
| AR099638A1 (es) | El uso de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio o una sal farmacéuticamente aceptable del mismo en la prevención y el tratamiento de la diabetes | |
| MX2016001357A (es) | Compuestos de ciclobutilo 1,2-disustituidos. |